Verlängerung der Dosierungsintervalle von IL‐17‐ und IL‐23‐Inhibitoren bei erwachsenen Patienten mit Psoriasis: eine Pilotstudie aus der Praxis

Deeskalationsstrategien für Biologika bei der Behandlung von Psoriasis sind in der klinischen Praxis weit verbreitet. Die Verlängerung des Dosierungsintervalls beinhaltet die Deeskalation der Zeitspanne zwischen den Injektionen biologischer Arzneimittel.

• Publication year

  2025

• Venue

  Journal der Deutschen Dermatologischen Gesellschaft

• Publication date

  2025-06-01

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1111/ddg.15686_gPMCID 12152519
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Treatment of Psoriasis Patients with Latent Tuberculosis Using IL-17 and IL-23 Inhibitors: A Retrospective, Multinational, Multicentre Study

  2024cited by this paper
• Dose reduction of dupilumab in atopic patients with controlled atopic dermatitis: A safe and effective practice?

  2023cited by this paper
• Efficacy of anti‐IL‐23 and anti‐IL‐17 after adalimumab failure in psoriatic patients

  2023cited by this paper
• Interleukin-17 vs. Interleukin-23 Inhibitors in Pustular and Erythrodermic Psoriasis: A Retrospective, Multicentre Cohort Study

  2023cited by this paper
• Reduced doses of biological therapies in psoriasis: a new potentially “sustainable” frontier of psoriasis treatment

  2023cited by this paper
• Successful tapering of dupilumab in atopic dermatitis patients with low disease activity: a large pragmatic daily practice study from the BioDay registry.

  2023cited by this paper
• Is risankizumab as needed administration a good option for patients with plaque psoriasis?

  2022cited by this paper
• Blocking interleukin‐17 in psoriasis: Real‐world experience from the PsoPlus cohort

  2022cited by this paper
• Biologic treatment for psoriasis in cancer patients: should they still be considered forbidden?

  2021cited by this paper
• Dose Tapering of Biologics in Patients with Psoriasis: A Scoping Review

  2021cited by this paper
• IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE)

  2021cited by this paper
• Dose reduction of the new generation biologics (IL-17 and IL-23 inhibitors) in psoriasis: study protocol for an international, pragmatic, multicenter, randomized, controlled, non-inferiority study—the BeNeBio study

  2021cited by this paper
• Secukinumab dosing optimization in patients with moderate‐to‐severe plaque psoriasis: results from the randomized, open‐label OPTIMISE study

  2020cited by this paper
• Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review.

  2020cited by this paper
• Comparison of Tightly Controlled Dose Reduction of Biologics With Usual Care for Patients With Psoriasis: A Randomized Clinical Trial.

  2020cited by this paper
• Polymorphisms associated with optimization of biological therapy through drug dose reduction in moderate‐to‐severe psoriasis

  2020cited by this paper
• Adalimumab Dose Tapering in Psoriasis: Predictive Factors for Maintenance of Complete Clearance.

  2017cited by this paper
• Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: Efficacy and safety results from a phase II randomized controlled study.

  2016cited by this paper
• Long‐term clinical safety and efficacy of brodalumab in the treatment of Japanese patients with moderate‐to‐severe plaque psoriasis

  2016cited by this paper
• Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis.

  2015cited by this paper
• Efficacy and safety of secukinumab in the treatment of moderate‐to‐severe plaque psoriasis: a randomized, double‐blind, placebo‐controlled phase II dose‐ranging study

  2013cited by this paper
• Adalimumab for psoriasis in Greece: clinical experience in a tertiary referral centre

  2012cited by this paper

• No citing papers are available for this paper.